CA2263425A1 - Pharmaceutical agent containing rho kinase inhibitor - Google Patents

Pharmaceutical agent containing rho kinase inhibitor

Info

Publication number
CA2263425A1
CA2263425A1 CA002263425A CA2263425A CA2263425A1 CA 2263425 A1 CA2263425 A1 CA 2263425A1 CA 002263425 A CA002263425 A CA 002263425A CA 2263425 A CA2263425 A CA 2263425A CA 2263425 A1 CA2263425 A1 CA 2263425A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
agent
alkyl
kinase inhibitor
rho kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002263425A
Other languages
French (fr)
Other versions
CA2263425C (en
Inventor
Masayoshi Uehata
Takashi Ono
Hiroyuki Satoh
Keiji Yamagami
Toshio Kawahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Yoshitomi Pharmaceutical Industries Ltd.
Masayoshi Uehata
Takashi Ono
Hiroyuki Satoh
Keiji Yamagami
Toshio Kawahara
Welfide Corporation
Mitsubishi Pharma Corporation
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16622116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2263425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yoshitomi Pharmaceutical Industries Ltd., Masayoshi Uehata, Takashi Ono, Hiroyuki Satoh, Keiji Yamagami, Toshio Kawahara, Welfide Corporation, Mitsubishi Pharma Corporation, Mitsubishi Tanabe Pharma Corporation filed Critical Yoshitomi Pharmaceutical Industries Ltd.
Publication of CA2263425A1 publication Critical patent/CA2263425A1/en
Application granted granted Critical
Publication of CA2263425C publication Critical patent/CA2263425C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug, containing an amide compound of the formula:

Ra-CO-NR b R c (I) in which R a is an amino(alkyl)-substituted cyclohexyl, an amino(alkyl)-substituted phenyl, pyperidyl or the like, R b is hydrogen, alkyl or the like and R c is optionally substituted N-containing heterocycle. Also disclosed a novel amide compound of the formula:

(see formula III) in which L and R5 are hydrogen, alkyl or the like and Rc' is optionally substituted heterocycle other than pyridine.
CA002263425A 1996-08-12 1997-08-08 Pharmaceutical agent containing rho kinase inhibitor Expired - Lifetime CA2263425C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21240996 1996-08-12
JP212409/1996 1996-08-12
PCT/JP1997/002793 WO1998006433A1 (en) 1996-08-12 1997-08-08 MEDICINES COMPRISING Rho KINASE INHIBITOR

Publications (2)

Publication Number Publication Date
CA2263425A1 true CA2263425A1 (en) 1998-02-19
CA2263425C CA2263425C (en) 2008-09-30

Family

ID=16622116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263425A Expired - Lifetime CA2263425C (en) 1996-08-12 1997-08-08 Pharmaceutical agent containing rho kinase inhibitor

Country Status (26)

Country Link
US (3) US6218410B1 (en)
EP (1) EP0956865B2 (en)
JP (1) JP3669711B2 (en)
KR (2) KR100595740B1 (en)
CN (1) CN100389828C (en)
AT (1) ATE359822T1 (en)
AU (1) AU738620B2 (en)
BG (4) BG63992B1 (en)
BR (1) BR9711154A (en)
CA (1) CA2263425C (en)
CZ (1) CZ301044B6 (en)
DE (1) DE69737631T3 (en)
DK (1) DK0956865T4 (en)
EE (1) EE9900050A (en)
ES (1) ES2286834T5 (en)
HK (1) HK1022436A1 (en)
HU (1) HU229864B1 (en)
IL (1) IL128456A0 (en)
IS (1) IS4973A (en)
NO (1) NO990622L (en)
NZ (2) NZ513800A (en)
PL (1) PL331561A1 (en)
PT (1) PT956865E (en)
RU (3) RU2206321C2 (en)
SI (1) SI0956865T2 (en)
WO (1) WO1998006433A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0956865T2 (en) * 1996-08-12 2011-04-29 Mitsubishi Pharma Corp MEDICINES COMPRISING Rho KINASE INHIBITOR
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
EP1074545A4 (en) * 1998-04-23 2001-08-22 Hiroyoshi Hidaka Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
EP1459743B9 (en) * 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
AU3196900A (en) * 1999-03-25 2000-10-16 Welfide Corporation Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
CN1358102A (en) * 1999-04-22 2002-07-10 三菱制药株式会社 Preventives/remedies for angiostenosis
CA2369560C (en) * 1999-04-27 2011-02-01 Makoto Nakamuta Agent for prophylaxis and treatment of liver disease
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
JP2001081031A (en) * 1999-08-30 2001-03-27 Schering Ag Benzamide derivative-containing preparation having improved solubility and oral adsorption
AU6865100A (en) * 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
WO2001022997A1 (en) * 1999-09-29 2001-04-05 Mitsubishi Pharma Corporation Analgesics
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ATE327993T1 (en) * 2000-03-16 2006-06-15 Mitsubishi Pharma Corp AMIDE COMPOUND AND USE THEREOF
JP4776138B2 (en) * 2000-03-31 2011-09-21 田辺三菱製薬株式会社 Kidney disease prevention and treatment
ATE465756T1 (en) * 2000-06-23 2010-05-15 Mitsubishi Tanabe Pharma Corp ANTITUMOR EFFECT AMPLIFIER
JP2004509875A (en) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 4-aminoquinazoline
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
JP4582561B2 (en) * 2000-10-23 2010-11-17 旭化成ファーマ株式会社 Inhibitor of vascular lesions caused by transplantation
JP2002139493A (en) * 2000-11-01 2002-05-17 Sumitomo Pharmaceut Co Ltd Novel high throughput screening method
CA2325842C (en) * 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
US20020132832A1 (en) * 2001-01-05 2002-09-19 Mills Thomas M. Treatment of erectile dysfunction
JP2002226375A (en) * 2001-01-31 2002-08-14 Asahi Kasei Corp Agent for preventing and treating fibrosis
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
AU2002245709A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
AR035791A1 (en) * 2001-03-23 2004-07-14 Bayer Corp COMPOUND N, N-DIHETEROCICLICO OF AMINA, INHIBITOR OF THE RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE COMPOUND
CN101310771B (en) * 2001-04-11 2012-08-08 千寿制药株式会社 Visual function disorder improving agents
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma Rho KINASE INHIBITORS
JP5042419B2 (en) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 Bone formation promoter and composition for promoting bone formation
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE10153605A1 (en) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Use of inhibitors of Rho kinases to stimulate nerve growth, to inhibit scar tissue formation and / or to reduce secondary damage
WO2003047591A1 (en) * 2001-11-30 2003-06-12 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
FR2833840B1 (en) * 2001-12-21 2010-06-18 Rytek METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY PATHOLOGIES
AU2003202263A1 (en) * 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
CN100354264C (en) * 2002-07-22 2007-12-12 旭化成制药株式会社 5-substituted isoquinoline derivatives
DE10233737A1 (en) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Use of modulators of the signal transduction pathway via the protein kinase Fyn for the treatment of tumor diseases
WO2004016739A2 (en) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein
ATE546143T1 (en) 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd AGENT FOR TREATING GLAUCOMA WITH A RHO-KINASE INHIBITOR AND PROSTAGLANDINS
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7615564B2 (en) 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4314433B2 (en) 2002-11-18 2009-08-19 参天製薬株式会社 Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
KR101224235B1 (en) 2003-04-11 2013-01-25 메디뮨 엘엘씨 Recombinant IL-9 Antibodies and Uses Thereof
ATE525111T1 (en) * 2003-04-18 2011-10-15 Senju Pharma Co 2-CHLORO-6,7-DIMETHOXY-N-5 Ä5-(1)H-INDAZOLYLUQUINAZOLINE-4-AMINE, N-(1-BENZYL-4-PIPERIDINYL)-1H-INDAZOLE-5-AMINE DIHYDROCHLORIDE, 4-Ä2 -(2,3,4,5,6-
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20110098232A1 (en) * 2003-05-30 2011-04-28 Zeilig Charles E Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
EP1656156A2 (en) * 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
US20050069553A1 (en) * 2003-08-13 2005-03-31 Yi Zheng Chimeric peptides for the regulation of GTPases
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7371850B1 (en) 2003-08-20 2008-05-13 Myriad Genetics, Inc. Method and composition for reducing expression of ROCK-II
JP4110324B2 (en) 2003-10-15 2008-07-02 宇部興産株式会社 New indazole derivatives
US20050238666A1 (en) * 2003-12-05 2005-10-27 Williams David A Methods of enhancing stem cell engraftment
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
AU2004308911B2 (en) * 2003-12-22 2010-08-26 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1696958B1 (en) * 2003-12-22 2007-03-28 Alcon, Inc. Agents for treatment of glaucomatous retinopathy and optic neuropathy
CN1980929A (en) * 2004-02-24 2007-06-13 比奥阿克松医疗技术股份有限公司 4-substituted piperidine derivatives
WO2005094824A1 (en) * 2004-03-25 2005-10-13 East Carolina University Methods of enhancing cancer therapy by protecting nerve cells
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
EP2394662B1 (en) 2004-04-02 2018-03-21 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CA2529613C (en) * 2004-06-03 2013-10-01 Senju Pharmaceutical Co., Ltd. Agent for repairing corneal sensitivity containing amide compound
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879100B1 (en) 2004-12-09 2007-07-06 Lionel Bueno COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE PATHOLOGIES AND RETINA
AR054416A1 (en) * 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US20080269249A2 (en) * 2004-12-27 2008-10-30 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
WO2006088088A1 (en) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Pain remedy containing rock inhibitor
JP5153613B2 (en) 2005-03-18 2013-02-27 メディミューン，エルエルシー Antibody framework shuffle
CR9465A (en) 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
AU2006264043B2 (en) 2005-06-28 2012-04-26 Sanofi-Aventis Isoquinoline derivatives as inhibitors of Rho-kinase
RS52241B (en) 2005-07-26 2012-10-31 Sanofi Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
CN101228149B (en) 2005-07-26 2013-01-02 塞诺菲-安万特股份有限公司 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CN101253166B (en) 2005-08-30 2013-07-10 旭化成制药株式会社 Sulfonamide compound
CN101253152A (en) 2005-09-02 2008-08-27 安斯泰来制药株式会社 Amide derivatives as ROCK inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
JP4832051B2 (en) * 2005-10-21 2011-12-07 学校法人順天堂 Treatment for crescent-forming kidney lesions
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7655662B2 (en) * 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド 5HT receptor-mediated neurogenesis
TW200815398A (en) 2006-06-08 2008-04-01 Ube Industries A novel indazole derivative having spirocyclic structure in the side chain
CA2659687A1 (en) * 2006-07-31 2008-02-07 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing amide compound
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
EP2064243A2 (en) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (en) * 2006-12-21 2009-04-01 Alcon Mfg Ltd OPHTHALMIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF ANALOGS OF 6-AMINOIMIDAZO [1,2B] PIRIDAZINAS, USEFUL FOR THE TREATMENT OF GLAUCOMA AND / OR CONTROL THE NORMAL OR ELEVATED INTRAOCULAR PRESSURE (IOP).
CA2673918C (en) 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2008077550A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AU2007338412B2 (en) 2006-12-27 2013-03-14 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
CA2673921C (en) 2006-12-27 2015-10-20 Sanofi-Aventis New substituted isoquinoline and isoquinolinone derivatives
CN101611012B (en) 2006-12-27 2012-11-14 塞诺菲-安万特股份有限公司 Cycloalkylamine substituted isoquinoline derivatives
JP5419279B2 (en) * 2007-01-17 2014-02-19 ウィスコンシン アラムニ リサーチ ファンデーション Improved stem cell culture
WO2008105058A1 (en) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamides
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
KR101566171B1 (en) 2007-03-09 2015-11-06 삼성전자 주식회사 Method and apparatus for digital rights management
JP5456658B2 (en) 2007-03-30 2014-04-02 メディミューン，エルエルシー Antibody preparation
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
US8232292B2 (en) 2007-07-02 2012-07-31 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2697895C (en) * 2007-08-29 2017-10-31 Senju Pharmaceutical Co., Ltd. Agent for promoting corneal endothelial cell adhesion
EP2296472A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc Compounds for rho kinase inhibition and for improving learning and memory
NZ590067A (en) 2008-06-24 2012-09-28 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors
PL2303846T3 (en) 2008-06-24 2015-10-30 Sanofi Sa Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
DK2313374T3 (en) 2008-06-24 2013-12-16 Sanofi Sa 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES
KR20110042054A (en) 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Prophylactic or therapeutic agent for axial myopia
US20110166161A1 (en) * 2008-09-18 2011-07-07 Astellas Pharma Inc. Heterocyclic carboxamide compounds
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CR20170089A (en) 2009-04-03 2017-07-17 Plexxikon Inc PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
ES2938049T3 (en) 2009-10-16 2023-04-04 Scripps Research Inst Induction of stem cells
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102188697B (en) * 2010-03-03 2014-11-05 中国医学科学院药物研究所 Application of recombinant human Rho kinase to preparation of medicaments
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
CN114164167A (en) 2010-12-22 2022-03-11 菲特治疗公司 Cell culture platform for single cell sorting and enhanced IPSC reprogramming
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
MA34948B1 (en) 2011-02-07 2014-03-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
US9273006B2 (en) * 2012-05-08 2016-03-01 Syddansk Universitet Anabolic compounds for treating and preventing bone loss diseases
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptides comprising non-natural amino acids and methods of making and using the same
CN105050600B (en) 2013-04-24 2018-09-28 国立大学法人九州大学 Fundus oculi disease therapeutic agent
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
SG11201509982UA (en) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
RU2699289C2 (en) 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. Nucleic acids encoding human antibodies to sialyl-lewisa
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PT3154583T (en) 2014-06-04 2021-03-24 Biontech Res And Development Inc Human monoclonal antibodies to ganglioside gd2
KR20170020527A (en) 2014-06-27 2017-02-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
EP3229838B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
PT3313449T (en) 2015-06-24 2020-10-30 Nitto Denko Corp Ionizable compounds and compositions and uses thereof
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CN117737124A (en) 2015-10-16 2024-03-22 菲特治疗公司 Platform for inducing and maintaining ground state pluripotency
KR20180100122A (en) 2015-12-02 2018-09-07 주식회사 에스티사이언스 Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
AU2016365318B2 (en) 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CN110997724A (en) 2017-06-06 2020-04-10 斯特库伯株式会社 Methods of treating cancer using antibodies and molecules that bind BTN1A1 or BTN1A 1-ligands
WO2019014322A1 (en) * 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
EP4338751A2 (en) 2017-12-21 2024-03-20 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
BR112021000934A2 (en) 2018-07-20 2021-04-27 Pierre Fabre Medicament receiver for sight
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
UY38427A (en) 2018-10-26 2020-05-29 Novartis Ag METHODS AND COMPOSITIONS FOR EYE CELL THERAPY
CN111116555B (en) * 2018-10-30 2023-06-02 北京盈科瑞创新药物研究有限公司 Rho kinase inhibitor and preparation method and application thereof
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
EP4142879A1 (en) 2020-04-27 2023-03-08 Novartis AG Methods and compositions for ocular cell therapy
CN111707831A (en) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition
KR20230157307A (en) 2021-01-11 2023-11-16 인사이트 코포레이션 Combination therapy involving JAK pathway inhibitors and ROCK inhibitors
CN113262226B (en) * 2021-04-19 2023-05-16 杭州市第一人民医院 Application of Li Shude mol in preparation of bacterial infection treatment drugs
WO2023069949A1 (en) 2021-10-18 2023-04-27 Evia Life Sciences Inc. Compositions and methods of use thereof for treating liver fibrosis
WO2023067394A2 (en) 2021-10-22 2023-04-27 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0227992B2 (en) 1982-01-14 1990-06-20 Asahi Kasei Kogyo Kk ISOKINORINSURUHONIRUKAGOBUTSU
JPS57200366A (en) * 1981-06-01 1982-12-08 Asahi Chem Ind Co Ltd Isoquinoline compound
JPS58121278A (en) 1982-01-12 1983-07-19 Asahi Chem Ind Co Ltd Isoquinolinesulfonic acid amide derivative
US4456757A (en) † 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (en) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd Isoquinolinesulfonic acid amide derivative
JPS6081168A (en) 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd Amidine derivative
JPS61152658A (en) 1984-12-27 1986-07-11 Asahi Chem Ind Co Ltd Substituted isoquinolinesulfonamide derivative
JPS61227581A (en) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd Isoquinoline derivative bearing sulfone group
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
DE3583287D1 (en) * 1984-12-27 1991-07-25 Asahi Chemical Ind SUBSTITUTED ISOCHINOLINSULFONYL COMPOUNDS.
JPH0680054B2 (en) * 1985-06-19 1994-10-12 吉富製薬株式会社 Piperidine derivative
JPH062741B2 (en) 1985-10-29 1994-01-12 旭化成工業株式会社 Secondary isoquinoline sulfonamide derivative
JP2770497B2 (en) * 1988-11-24 1998-07-02 吉富製薬株式会社 Trans-4-amino (alkyl) -1-pyridylcarbamoylcyclohexane compounds and their pharmaceutical uses
WO1990005723A1 (en) † 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
JP2720348B2 (en) * 1989-03-30 1998-03-04 旭化成工業株式会社 Brain cell dysfunction improver
JP3408546B2 (en) * 1991-02-19 2003-05-19 旭化成株式会社 Anti-asthmatic
JP2864489B2 (en) * 1991-02-27 1999-03-03 吉富製薬株式会社 Asthma treatment
JP3275389B2 (en) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 4-amino (alkyl) cyclohexane-1-carboxylic acid amide compound
EP0641781B1 (en) 1991-09-06 2000-07-26 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
JPH05273821A (en) 1992-03-24 1993-10-22 Nippon Steel Corp Electrostatic image forming device
JP3265695B2 (en) * 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 4-substituted amino (alkyl) cyclohexane-1-carboxylic acid amide compound
JP2893029B2 (en) * 1992-08-10 1999-05-17 旭化成工業株式会社 Cardioprotectant
JPH0680569A (en) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd Antithrombotic agent
JP3218356B2 (en) 1993-03-31 2001-10-15 ヤンマー農機株式会社 Management machine
JPH06289679A (en) * 1993-04-01 1994-10-18 Hitachi Metals Ltd Image forming method
JP3464012B2 (en) * 1993-04-05 2003-11-05 旭化成株式会社 Psychotic treatment
DE4323295C1 (en) * 1993-07-12 1995-02-09 Manfred R Dr Hamm Dosing device
JPH0741424A (en) * 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd Anti-inflammatory agent
JPH07277979A (en) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd Therapeutic or preventive agent for hyperviscosity syndrome
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
SI0956865T2 (en) * 1996-08-12 2011-04-29 Mitsubishi Pharma Corp MEDICINES COMPRISING Rho KINASE INHIBITOR

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169783B2 (en) 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion

Also Published As

Publication number Publication date
ES2286834T5 (en) 2011-01-31
US6451825B1 (en) 2002-09-17
CZ46099A3 (en) 1999-07-14
HK1022436A1 (en) 2000-08-11
EE9900050A (en) 1999-08-16
EP0956865A4 (en) 2001-05-16
WO1998006433A1 (en) 1998-02-19
DE69737631T2 (en) 2007-12-27
SI0956865T1 (en) 2007-10-31
PL331561A1 (en) 1999-07-19
BG107195A (en) 2003-05-30
HU229864B1 (en) 2014-10-28
CN100389828C (en) 2008-05-28
AU738620B2 (en) 2001-09-20
CZ301044B6 (en) 2009-10-21
EP0956865A1 (en) 1999-11-17
DK0956865T4 (en) 2010-11-22
ATE359822T1 (en) 2007-05-15
BG63992B1 (en) 2003-09-30
DE69737631D1 (en) 2007-05-31
IL128456A0 (en) 2000-01-31
ES2286834T3 (en) 2007-12-01
JP3669711B2 (en) 2005-07-13
SI0956865T2 (en) 2011-04-29
RU2206321C2 (en) 2003-06-20
HUP9903694A2 (en) 2000-03-28
BG63991B1 (en) 2003-09-30
RU2003103606A (en) 2004-08-27
IS4973A (en) 1999-02-11
NO990622L (en) 1999-04-12
KR20000029918A (en) 2000-05-25
KR100576148B1 (en) 2006-05-03
NZ513800A (en) 2001-09-28
AU3785197A (en) 1998-03-06
KR20050055022A (en) 2005-06-10
US6218410B1 (en) 2001-04-17
EP0956865B2 (en) 2010-08-18
NO990622D0 (en) 1999-02-10
CA2263425C (en) 2008-09-30
BR9711154A (en) 1999-08-17
EP0956865B1 (en) 2007-04-18
HUP9903694A3 (en) 2002-10-28
US20020032148A1 (en) 2002-03-14
PT956865E (en) 2007-07-30
CN1233188A (en) 1999-10-27
KR100595740B1 (en) 2006-07-03
DK0956865T3 (en) 2007-09-03
US6906061B2 (en) 2005-06-14
RU2003104284A (en) 2004-08-27
US20030134775A1 (en) 2003-07-17
BG107645A (en) 2004-05-31
BG103246A (en) 2000-05-31
NZ334613A (en) 2002-02-01
DE69737631T3 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
CA2263425A1 (en) Pharmaceutical agent containing rho kinase inhibitor
RU99104798A (en) PHARMACEUTICAL AGENT CONTAINING RHO-KINASE INHIBITOR
DK0874824T3 (en) Trisubstituted phenyl derivatives useful as PDE IV inhibitors
CA2316921A1 (en) Aryl fused azapolycyclic compounds
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
EP1797875A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
FR2712591B1 (en) New arylpiperazines derived from indole, their preparation and their therapeutic use.
CA2119647A1 (en) Heteroaryl Amines as Novel Acetylcholinesterase Inhibitors
EP0382687A3 (en) Benzofused-n-containing heterocycle derivatives
CA2245267A1 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
RU94046141A (en) Substituted(arylalkoxybenzyl)aminopropaneamide derivatives, processes for preparation thereof, and pharmaceutical composition
BG104243A (en) Method for the synthesis of quinoline derivatives
CA2278057A1 (en) Tachykinin antagonists
AU660969B2 (en) NMDA antagonists
WO2002058680A3 (en) Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
CA2237401A1 (en) Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
CA2168265A1 (en) Antidepressant
RU95102147A (en) 1-[2-(1h-inden-3-yl)ethyl]-4-(napht-1-yl)preparazine derivatives, process for preparation thereof, and drug and pharmaceutical composition containing said derivatives, and pharmaceutical composition
NO974197L (en) Process for the preparation of esters of anhydroecgonine
EP1600452A3 (en) Synthesis of 2'-deoxy-L-nucleosides
RU92016278A (en) INDOLA DERIVATIVES

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170808